BI 10773 (Empagliflozin) Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME).
A Phase III, Multicentre, International, Randomised, Parallel Group, Double Blind Cardiovascular Safety Study of BI 10773 (10 mg and 25 mg Administered Orally Once Daily) Compared to Usual Care in Type 2 Diabetes Mellitus Patients With Increased Cardiovascular Risk
2 other identifiers
interventional
7,064
40 countries
589
Brief Summary
The aim of the present study is to investigate the safety of BI 10773 treatment in patients with Type 2 Diabetes Mellitus and high cardiovascular risk.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for phase_3 diabetes-mellitus-type-2
Started Jul 2010
Longer than P75 for phase_3 diabetes-mellitus-type-2
589 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
May 26, 2010
CompletedFirst Posted
Study publicly available on registry
May 27, 2010
CompletedStudy Start
First participant enrolled
July 1, 2010
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 1, 2015
CompletedStudy Completion
Last participant's last visit for all outcomes
April 1, 2015
CompletedResults Posted
Study results publicly available
May 16, 2016
CompletedMay 16, 2016
April 1, 2016
4.8 years
May 26, 2010
April 7, 2016
April 7, 2016
Conditions
Outcome Measures
Primary Outcomes (1)
Time to the First Occurrence of Any of the Following Adjudicated Components of the Primary Composite Endpoint (3-point MACE): CV Death (Including Fatal Stroke and Fatal MI), Non-fatal MI (Excluding Silent MI), and Non-fatal Stroke.
Time to the first occurrence of any of the following adjudicated components of the primary composite endpoint (3-point major adverse cardiovascular events (MACE)): cardiovascular (CV) death (including fatal stroke and fatal myocardial infarction (MI)), non-fatal MI (excluding silent MI), and non-fatal stroke. Percentage of patients with the event are presented.
From randomisation to individual end of observation, up to 4.6 years
Secondary Outcomes (6)
Percentage of Participants With the Composite of All Events Adjudicated (4-point MACE): CV Death (Including Fatal Stroke and Fatal MI), Non-fatal MI (Excluding Silent MI), Non-fatal Stroke and Hospitalization for Unstable Angina Pectoris
From randomisation to individual end of observation, up to 4.6 years
Percentage of Participants With Silent MI
From randomisation to individual end of observation, up to 4.6 years
Percentage of Participants With Heart Failure Requiring Hospitalisation (Adjudicated)
From randomisation to individual end of observation, up to 4.6 years
Percentage of Participants With New Onset Albuminuria
From randomisation to individual end of observation, up to 4.6 years
Percentage of Participants With New Onset Macroalbuminuria
From randomisation to individual end of observation, up to 4.6 years
- +1 more secondary outcomes
Study Arms (3)
BI 10773 low dose
EXPERIMENTALBI 10773 tablets once daily
BI 10773 high dose
EXPERIMENTALBI 10773 tablets once daily
Placebo
PLACEBO COMPARATORPlacebo tablets matching BI 10773
Interventions
Eligibility Criteria
You may qualify if:
- Diagnosis of type 2 diabetes mellitus prior to informed consent
- Male or female patients on diet and exercise regimen who are drug naive or pre treated with any background therapy. Antidiabetic therapy has to be unchanged for 12 weeks prior to randomization.
- Glycosylated haemoglobin (HbA1c) of \>= 7.0% and \<=10% for patients on background therapy or HbA1c \>= 7.0% and \<= 9.0% for drug naive patients
- Age \>= 18 years
- Body Mass index \<= 45 at Visit 1
- Signed and dated informed consent
- High cardiovascular risk
You may not qualify if:
- Uncontrolled hyperglycaemia with a glucose level \>240 mg/dl (\>13.3 mmol/L) after an overnight fast during placebo run-in and confirmed by a second measurement (not on the same day)
- Indication of liver disease, defined by serum levels of either alanine aminotransferase (ALT), aspartate aminotransferase ALT or alkaline phosphatase above 3 x upper limit of normal (ULN) as determined at screening and/or run in.
- Planned cardiac surgery or angioplasty within 3 months
- Impaired renal function, defined as Glomerular Filtration Rate \<30 ml/min (severe renal impairment, Modification of Diet in Renal Disease formula) during screening or run in.
- Bariatric surgery within the past two years and other gastrointestinal surgeries that induce chronic malabsorption
- Blood dyscrasias or any disorders causing haemolysis or unstable Red Blood Cell (e.g. malaria, babesiosis, haemolytic anemia)
- Medical history of cancer (except for basal cell carcinoma) and/or treatment for cancer within the last 5 years
- Contraindications to background therapy according to the local label
- Treatment with anti-obesity drugs (e.g. sibutramine, orlistat) 3 months prior to informed consent or any other treatment at the time of screening (i.e. surgery, aggressive diet regimen, etc.) leading to unstable body weight
- Current treatment with systemic steroids at time of informed consent or change in dosage of thyroid hormones within 6 weeks prior to informed consent or any other uncontrolled endocrine disorder except type 2 diabetes mellitus
- Pre-menopausal women (last menstruation \<+ 1 year prior to informed consent) who:
- are nursing or pregnant or
- are of child-bearing potential and are not practicing an acceptable method of birth control, or do not plan to continue using this method throughout the study and do not agree to submit to periodic pregnancy testing during participation in the trial. Acceptable methods of birth control include tubal ligation, transdermal patch, intra uterine devices/systems, oral, implantable or injectable contraceptives, sexual abstinence, double barrier method and vasectomised partner
- Alcohol or drug abuse within the 3 months prior to informed consent that would interfere with trial participation or any ongoing condition leading to a decreased compliance to study procedures or study drug intake
- Participation in another trial with an investigational drug within 30 days prior to informed consent
- +2 more criteria
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Boehringer Ingelheimlead
- Eli Lilly and Companycollaborator
Study Sites (615)
1245.25.10043 Boehringer Ingelheim Investigational Site
Birmingham, Alabama, United States
1245.25.10121 Boehringer Ingelheim Investigational Site
Birmingham, Alabama, United States
1245.25.10037 Boehringer Ingelheim Investigational Site
Huntsville, Alabama, United States
1245.25.10124 Boehringer Ingelheim Investigational Site
Mobile, Alabama, United States
1245.25.10015 Boehringer Ingelheim Investigational Site
Little Rock, Alaska, United States
1245.25.10056 Boehringer Ingelheim Investigational Site
Gilbert, Arizona, United States
1245.25.10175 Boehringer Ingelheim Investigational Site
Peoria, Arizona, United States
1245.25.10072 Boehringer Ingelheim Investigational Site
Phoenix, Arizona, United States
1245.25.10048 Boehringer Ingelheim Investigational Site
Harrisburg, Arkansas, United States
1245.25.10035 Boehringer Ingelheim Investigational Site
Anaheim, California, United States
1245.25.10103 Boehringer Ingelheim Investigational Site
Encino, California, United States
1245.25.10158 Boehringer Ingelheim Investigational Site
Fresno, California, United States
1245.25.10126 Boehringer Ingelheim Investigational Site
Harbor City, California, United States
1245.25.10058 Boehringer Ingelheim Investigational Site
Huntington Park, California, United States
1245.25.10001 Boehringer Ingelheim Investigational Site
Lancaster, California, United States
1245.25.10102 Boehringer Ingelheim Investigational Site
Los Angeles, California, United States
1245.25.10047 Boehringer Ingelheim Investigational Site
Los Gatos, California, United States
1245.25.10118 Boehringer Ingelheim Investigational Site
Palm Springs, California, United States
1245.25.10061 Boehringer Ingelheim Investigational Site
Riverside, California, United States
1245.25.10040 Boehringer Ingelheim Investigational Site
San Diego, California, United States
1245.25.10055 Boehringer Ingelheim Investigational Site
San Diego, California, United States
1245.25.10193 Boehringer Ingelheim Investigational Site
San Diego, California, United States
1245.25.10027 Boehringer Ingelheim Investigational Site
Santa Rosa, California, United States
1245.25.10074 Boehringer Ingelheim Investigational Site
Stockton, California, United States
1245.25.10083 Boehringer Ingelheim Investigational Site
Valencia, California, United States
1245.25.10144 Boehringer Ingelheim Investigational Site
Colorado Springs, Colorado, United States
1245.25.10085 Boehringer Ingelheim Investigational Site
Denver, Colorado, United States
1245.25.10153 Boehringer Ingelheim Investigational Site
Denver, Colorado, United States
1245.25.10066 Boehringer Ingelheim Investigational Site
Norwalk, Connecticut, United States
1245.25.10038 Boehringer Ingelheim Investigational Site
Waterbury, Connecticut, United States
1245.25.10068 Boehringer Ingelheim Investigational Site
Washington D.C., District of Columbia, United States
1245.25.10094 Boehringer Ingelheim Investigational Site
Bradenton, Florida, United States
1245.25.10190 Boehringer Ingelheim Investigational Site
Brooksville, Florida, United States
1245.25.10209 Boehringer Ingelheim Investigational Site
Clearwater, Florida, United States
1245.25.10212 Boehringer Ingelheim Investigational Site
Cooper City, Florida, United States
1245.25.10200 Boehringer Ingelheim Investigational Site
Delray Beach, Florida, United States
1245.25.10033 Boehringer Ingelheim Investigational Site
Fort Lauderdale, Florida, United States
1245.25.10202 Boehringer Ingelheim Investigational Site
Hallandale, Florida, United States
1245.25.10062 Boehringer Ingelheim Investigational Site
Hialeah, Florida, United States
1245.25.10063 Boehringer Ingelheim Investigational Site
Hialeah, Florida, United States
1245.25.10157 Boehringer Ingelheim Investigational Site
Hialeah, Florida, United States
1245.25.10089 Boehringer Ingelheim Investigational Site
Jacksonville, Florida, United States
1245.25.10019 Boehringer Ingelheim Investigational Site
Longwood, Florida, United States
1245.25.10168 Boehringer Ingelheim Investigational Site
Maitland, Florida, United States
1245.25.10018 Boehringer Ingelheim Investigational Site
Miami, Florida, United States
1245.25.10039 Boehringer Ingelheim Investigational Site
Miami, Florida, United States
1245.25.10184 Boehringer Ingelheim Investigational Site
Miami, Florida, United States
1245.25.10123 Boehringer Ingelheim Investigational Site
Orlando, Florida, United States
1245.25.10201 Boehringer Ingelheim Investigational Site
Orlando, Florida, United States
1245.25.10025 Boehringer Ingelheim Investigational Site
Pembroke Pines, Florida, United States
1245.25.10042 Boehringer Ingelheim Investigational Site
Pembroke Pines, Florida, United States
1245.25.10147 Boehringer Ingelheim Investigational Site
Port Charlotte, Florida, United States
1245.25.10198 Boehringer Ingelheim Investigational Site
St. Petersburg, Florida, United States
1245.25.10203 Boehringer Ingelheim Investigational Site
St. Petersburg, Florida, United States
1245.25.10104 Boehringer Ingelheim Investigational Site
Tampa, Florida, United States
1245.25.10178 Boehringer Ingelheim Investigational Site
Tampa, Florida, United States
1245.25.10211 Boehringer Ingelheim Investigational Site
Tampa, Florida, United States
1245.25.10023 Boehringer Ingelheim Investigational Site
Atlanta, Georgia, United States
1245.25.10174 Boehringer Ingelheim Investigational Site
Columbus, Georgia, United States
1245.25.10141 Boehringer Ingelheim Investigational Site
Riverdale, Georgia, United States
1245.25.10067 Boehringer Ingelheim Investigational Site
Roswell, Georgia, United States
1245.25.10022 Boehringer Ingelheim Investigational Site
Honolulu, Hawaii, United States
1245.25.10092 Boehringer Ingelheim Investigational Site
Boise, Idaho, United States
1245.25.10097 Boehringer Ingelheim Investigational Site
Chicago, Illinois, United States
1245.25.10116 Boehringer Ingelheim Investigational Site
Evansville, Indiana, United States
1245.25.10206 Boehringer Ingelheim Investigational Site
Valparaiso, Indiana, United States
1245.25.10021 Boehringer Ingelheim Investigational Site
Wichita, Kansas, United States
1245.25.10186 Boehringer Ingelheim Investigational Site
Lexington, Kentucky, United States
1245.25.10109 Boehringer Ingelheim Investigational Site
Louisville, Kentucky, United States
1245.25.10006 Boehringer Ingelheim Investigational Site
Madisonville, Kentucky, United States
1245.25.10005 Boehringer Ingelheim Investigational Site
Paducah, Kentucky, United States
1245.25.10020 Boehringer Ingelheim Investigational Site
New Orleans, Louisiana, United States
1245.25.10012 Boehringer Ingelheim Investigational Site
Auburn, Maine, United States
1245.25.10041 Boehringer Ingelheim Investigational Site
Baltimore, Maryland, United States
1245.25.10134 Boehringer Ingelheim Investigational Site
Hyattsville, Maryland, United States
1245.25.10210 Boehringer Ingelheim Investigational Site
Towson, Maryland, United States
1245.25.10064 Boehringer Ingelheim Investigational Site
Springfield, Massachusetts, United States
1245.25.10051 Boehringer Ingelheim Investigational Site
Watertown, Massachusetts, United States
1245.25.10071 Boehringer Ingelheim Investigational Site
Dearborn, Michigan, United States
1245.25.10013 Boehringer Ingelheim Investigational Site
Flint, Michigan, United States
1245.25.10107 Boehringer Ingelheim Investigational Site
Petoskey, Michigan, United States
1245.25.10030 Boehringer Ingelheim Investigational Site
Eagan, Minnesota, United States
1245.25.10028 Boehringer Ingelheim Investigational Site
Minneapolis, Minnesota, United States
1245.25.10176 Boehringer Ingelheim Investigational Site
Picayune, Mississippi, United States
1245.25.10011 Boehringer Ingelheim Investigational Site
Chesterfield, Missouri, United States
1245.25.10163 Boehringer Ingelheim Investigational Site
Kansas City, Missouri, United States
1245.25.10148 Boehringer Ingelheim Investigational Site
Great Falls, Montana, United States
1245.25.10191 Boehringer Ingelheim Investigational Site
Great Falls, Montana, United States
1245.25.10034 Boehringer Ingelheim Investigational Site
Omaha, Nebraska, United States
1245.25.10014 Boehringer Ingelheim Investigational Site
Flemington, New Jersey, United States
1245.25.10145 Boehringer Ingelheim Investigational Site
Albuquerque, New Mexico, United States
1245.25.10180 Boehringer Ingelheim Investigational Site
Albuquerque, New Mexico, United States
1245.25.10131 Boehringer Ingelheim Investigational Site
Binghamton, New York, United States
1245.25.10029 Boehringer Ingelheim Investigational Site
Rochester, New York, United States
1245.25.10142 Boehringer Ingelheim Investigational Site
Smithtown, New York, United States
1245.25.10096 Boehringer Ingelheim Investigational Site
Staten Island, New York, United States
1245.25.10196 Boehringer Ingelheim Investigational Site
Burlington, North Carolina, United States
1245.25.10207 Boehringer Ingelheim Investigational Site
Calabash, North Carolina, United States
1245.25.10053 Boehringer Ingelheim Investigational Site
Durham, North Carolina, United States
1245.25.10010 Boehringer Ingelheim Investigational Site
Greenville, North Carolina, United States
1245.25.10060 Boehringer Ingelheim Investigational Site
Cincinnati, Ohio, United States
1245.25.10086 Boehringer Ingelheim Investigational Site
Cincinnati, Ohio, United States
1245.25.10137 Boehringer Ingelheim Investigational Site
Dayton, Ohio, United States
1245.25.10138 Boehringer Ingelheim Investigational Site
Delaware, Ohio, United States
1245.25.10156 Boehringer Ingelheim Investigational Site
Kettering, Ohio, United States
1245.25.10091 Boehringer Ingelheim Investigational Site
Marion, Ohio, United States
1245.25.10192 Boehringer Ingelheim Investigational Site
Zanesville, Ohio, United States
1245.25.10114 Boehringer Ingelheim Investigational Site
Norman, Oklahoma, United States
1245.25.10082 Boehringer Ingelheim Investigational Site
Eugene, Oregon, United States
1245.25.10154 Boehringer Ingelheim Investigational Site
Clairton, Pennsylvania, United States
1245.25.10173 Boehringer Ingelheim Investigational Site
Clairton, Pennsylvania, United States
1245.25.10052 Boehringer Ingelheim Investigational Site
Feasterville-Trevose, Pennsylvania, United States
1245.25.10069 Boehringer Ingelheim Investigational Site
Fleetwood, Pennsylvania, United States
1245.25.10172 Boehringer Ingelheim Investigational Site
Greensburg, Pennsylvania, United States
1245.25.10050 Boehringer Ingelheim Investigational Site
Indiana, Pennsylvania, United States
1245.25.10009 Boehringer Ingelheim Investigational Site
Lansdale, Pennsylvania, United States
1245.25.10214 Boehringer Ingelheim Investigational Site
Philadelphia, Pennsylvania, United States
1245.25.10149 Boehringer Ingelheim Investigational Site
Pittsburgh, Pennsylvania, United States
1245.25.10197 Boehringer Ingelheim Investigational Site
Pittsburgh, Pennsylvania, United States
1245.25.10159 Boehringer Ingelheim Investigational Site
Scottdale, Pennsylvania, United States
1245.25.10162 Boehringer Ingelheim Investigational Site
Tipton, Pennsylvania, United States
1245.25.10146 Boehringer Ingelheim Investigational Site
Uniontown, Pennsylvania, United States
1245.25.10077 Boehringer Ingelheim Investigational Site
Yardley, Pennsylvania, United States
1245.25.10070 Boehringer Ingelheim Investigational Site
Anderson, South Carolina, United States
1245.25.10044 Boehringer Ingelheim Investigational Site
Charleston, South Carolina, United States
1245.25.10002 Boehringer Ingelheim Investigational Site
Greer, South Carolina, United States
1245.25.10132 Boehringer Ingelheim Investigational Site
Hodges, South Carolina, United States
1245.25.10140 Boehringer Ingelheim Investigational Site
Mt. Pleasant, South Carolina, United States
1245.25.10065 Boehringer Ingelheim Investigational Site
Myrtle Beach, South Carolina, United States
1245.25.10127 Boehringer Ingelheim Investigational Site
Myrtle Beach, South Carolina, United States
1245.25.10170 Boehringer Ingelheim Investigational Site
North Myrtle Beach, South Carolina, United States
1245.25.10129 Boehringer Ingelheim Investigational Site
Spartanburg, South Carolina, United States
1245.25.10171 Boehringer Ingelheim Investigational Site
Union, South Carolina, United States
1245.25.10054 Boehringer Ingelheim Investigational Site
Bristol, Tennessee, United States
1245.25.10036 Boehringer Ingelheim Investigational Site
Chattanooga, Tennessee, United States
1245.25.10057 Boehringer Ingelheim Investigational Site
Chattanooga, Tennessee, United States
1245.25.10046 Boehringer Ingelheim Investigational Site
Kingsport, Tennessee, United States
1245.25.10143 Boehringer Ingelheim Investigational Site
Memphis, Tennessee, United States
1245.25.10075 Boehringer Ingelheim Investigational Site
Corpus Christi, Texas, United States
1245.25.10007 Boehringer Ingelheim Investigational Site
Dallas, Texas, United States
1245.25.10026 Boehringer Ingelheim Investigational Site
Dallas, Texas, United States
1245.25.10100 Boehringer Ingelheim Investigational Site
Dallas, Texas, United States
1245.25.10165 Boehringer Ingelheim Investigational Site
Dallas, Texas, United States
1245.25.10169 Boehringer Ingelheim Investigational Site
Fort Worth, Texas, United States
1245.25.10003 Boehringer Ingelheim Investigational Site
Houston, Texas, United States
1245.25.10125 Boehringer Ingelheim Investigational Site
Houston, Texas, United States
1245.25.10189 Boehringer Ingelheim Investigational Site
Houston, Texas, United States
1245.25.10119 Boehringer Ingelheim Investigational Site
Lubbock, Texas, United States
1245.25.10078 Boehringer Ingelheim Investigational Site
New Braunfels, Texas, United States
1245.25.10076 Boehringer Ingelheim Investigational Site
Odessa, Texas, United States
1245.25.10133 Boehringer Ingelheim Investigational Site
Pearland, Texas, United States
1245.25.10160 Boehringer Ingelheim Investigational Site
Plano, Texas, United States
1245.25.10177 Boehringer Ingelheim Investigational Site
Richardson, Texas, United States
1245.25.10049 Boehringer Ingelheim Investigational Site
San Antonio, Texas, United States
1245.25.10161 Boehringer Ingelheim Investigational Site
San Antonio, Texas, United States
1245.25.10185 Boehringer Ingelheim Investigational Site
Bountiful, Utah, United States
1245.25.10155 Boehringer Ingelheim Investigational Site
Draper, Utah, United States
1245.25.10079 Boehringer Ingelheim Investigational Site
Midvale, Utah, United States
1245.25.10080 Boehringer Ingelheim Investigational Site
Salt Lake City, Utah, United States
1245.25.10087 Boehringer Ingelheim Investigational Site
South Ogden, Utah, United States
1245.25.10218 Boehringer Ingelheim Investigational Site
Burke, Virginia, United States
1245.25.10004 Boehringer Ingelheim Investigational Site
Norfolk, Virginia, United States
1245.25.10111 Boehringer Ingelheim Investigational Site
South Chesterfield, Virginia, United States
1245.25.10115 Boehringer Ingelheim Investigational Site
Spokane, Washington, United States
1245.25.10216 Boehringer Ingelheim Investigational Site
Spokane, Washington, United States
1245.25.10017 Boehringer Ingelheim Investigational Site
Tacoma, Washington, United States
1245.25.10016 Boehringer Ingelheim Investigational Site
Walla Walla, Washington, United States
1245.25.10187 Boehringer Ingelheim Investigational Site
Charleston, West Virginia, United States
1245.25.10182 Boehringer Ingelheim Investigational Site
Morgantown, West Virginia, United States
1245.25.10098 Boehringer Ingelheim Investigational Site
Madison, Wisconsin, United States
1245.25.54012 Boehringer Ingelheim Investigational Site
Buenos Aires, Argentina
1245.25.54001 Boehringer Ingelheim Investigational Site
Capital Federal, Argentina
1245.25.54006 Boehringer Ingelheim Investigational Site
Capital Federal, Argentina
1245.25.54013 Boehringer Ingelheim Investigational Site
Capital Federal, Argentina
1245.25.54002 Boehringer Ingelheim Investigational Site
Córdoba, Argentina
1245.25.54003 Boehringer Ingelheim Investigational Site
Córdoba, Argentina
1245.25.54010 Boehringer Ingelheim Investigational Site
Córdoba, Argentina
1245.25.54011 Boehringer Ingelheim Investigational Site
Córdoba, Argentina
1245.25.54005 Boehringer Ingelheim Investigational Site
Parque Velez Sarfield, Argentina
1245.25.54008 Boehringer Ingelheim Investigational Site
Rosario, Argentina
1245.25.54009 Boehringer Ingelheim Investigational Site
Rosario, Argentina
1245.25.61003 Boehringer Ingelheim Investigational Site
Herston, Queensland, Australia
1245.25.61001 Boehringer Ingelheim Investigational Site
Ashford, South Australia, Australia
1245.25.61002 Boehringer Ingelheim Investigational Site
Fullarton, South Australia, Australia
1245.25.43008 Boehringer Ingelheim Investigational Site
Feldkirch, Austria
1245.25.43006 Boehringer Ingelheim Investigational Site
Graz, Austria
1245.25.43016 Boehringer Ingelheim Investigational Site
Innsbruck, Austria
1245.25.43005 Boehringer Ingelheim Investigational Site
Salzburg, Austria
1245.25.43015 Boehringer Ingelheim Investigational Site
St. Stefan, Austria
1245.25.43001 Boehringer Ingelheim Investigational Site
Vienna, Austria
1245.25.43007 Boehringer Ingelheim Investigational Site
Vienna, Austria
1245.25.43009 Boehringer Ingelheim Investigational Site
Vienna, Austria
1245.25.43010 Boehringer Ingelheim Investigational Site
Vienna, Austria
1245.25.43013 Boehringer Ingelheim Investigational Site
Vienna, Austria
1245.25.32010 Boehringer Ingelheim Investigational Site
Bonheiden, Belgium
1245.25.32008 Boehringer Ingelheim Investigational Site
Brussels, Belgium
1245.25.32011 Boehringer Ingelheim Investigational Site
Brussels, Belgium
1245.25.32030 Boehringer Ingelheim Investigational Site
Brussels, Belgium
1245.25.32003 Boehringer Ingelheim Investigational Site
De Pinte, Belgium
1245.25.32002 Boehringer Ingelheim Investigational Site
Edegem, Belgium
1245.25.32004 Boehringer Ingelheim Investigational Site
Genk, Belgium
1245.25.32029 Boehringer Ingelheim Investigational Site
Halen, Belgium
1245.25.32009 Boehringer Ingelheim Investigational Site
Hasselt, Belgium
1245.25.32007 Boehringer Ingelheim Investigational Site
Huy, Belgium
1245.25.32013 Boehringer Ingelheim Investigational Site
La Louvière, Belgium
1245.25.32012 Boehringer Ingelheim Investigational Site
Leuven, Belgium
1245.25.32001 Boehringer Ingelheim Investigational Site
Liège, Belgium
1245.25.32028 Boehringer Ingelheim Investigational Site
Liège, Belgium
1245.25.32005 Boehringer Ingelheim Investigational Site
Massemen-Wetteren, Belgium
1245.25.32014 Boehringer Ingelheim Investigational Site
Oostham, Belgium
1245.25.55014 Boehringer Ingelheim Investigational Site
Belém, Brazil
1245.25.55019 Boehringer Ingelheim Investigational Site
Belo Horizonte, Brazil
1245.25.55007 Boehringer Ingelheim Investigational Site
Boqueirão, Brazil
1245.25.55015 Boehringer Ingelheim Investigational Site
Brasília, Brazil
1245.25.55027 Boehringer Ingelheim Investigational Site
Campinas, Brazil
1245.25.55028 Boehringer Ingelheim Investigational Site
Campinas, Brazil
1245.25.55025 Boehringer Ingelheim Investigational Site
Curitiba, Brazil
1245.25.55026 Boehringer Ingelheim Investigational Site
Fortaleza, Brazil
1245.25.55009 Boehringer Ingelheim Investigational Site
Goiânia, Brazil
1245.25.55002 Boehringer Ingelheim Investigational Site
Higienópolis, Brazil
1245.25.55022 Boehringer Ingelheim Investigational Site
Maringá, Brazil
1245.25.55017 Boehringer Ingelheim Investigational Site
Marília, Brazil
1245.25.55008 Boehringer Ingelheim Investigational Site
Porto Alegre, Brazil
1245.25.55016 Boehringer Ingelheim Investigational Site
Porto Alegre, Brazil
1245.25.55020 Boehringer Ingelheim Investigational Site
Porto Alegre, Brazil
1245.25.55012 Boehringer Ingelheim Investigational Site
Ribeirão Preto, Brazil
1245.25.55013 Boehringer Ingelheim Investigational Site
São José do Rio Preto, Brazil
1245.25.55004 Boehringer Ingelheim Investigational Site
São Paulo, Brazil
1245.25.55010 Boehringer Ingelheim Investigational Site
São Paulo, Brazil
1245.25.55018 Boehringer Ingelheim Investigational Site
São Paulo, Brazil
1245.25.55023 Boehringer Ingelheim Investigational Site
São Paulo, Brazil
1245.25.55006 Boehringer Ingelheim Investigational Site
Vila Albuquerque, Brazil
1245.25.55003 Boehringer Ingelheim Investigational Site
Vila Clementino, Brazil
1245.25.55005 Boehringer Ingelheim Investigational Site
Vila Leopoldina, Brazil
1245.25.55001 Boehringer Ingelheim Investigational Site
Villa Clementino, Brazil
1245.25.20047 Boehringer Ingelheim Investigational Site
Vancouver, British Columbia, Canada
1245.25.20048 Boehringer Ingelheim Investigational Site
Winnipeg, Manitoba, Canada
1245.25.20026 Boehringer Ingelheim Investigational Site
Halifax, Nova Scotia, Canada
1245.25.20045 Boehringer Ingelheim Investigational Site
Brampton, Ontario, Canada
1245.25.20042 Boehringer Ingelheim Investigational Site
Burlington, Ontario, Canada
1245.25.20009 Boehringer Ingelheim Investigational Site
Newmarket, Ontario, Canada
1245.25.20044 Boehringer Ingelheim Investigational Site
Niagara Falls, Ontario, Canada
1245.25.20013 Boehringer Ingelheim Investigational Site
Ottawa, Ontario, Canada
1245.25.20049 Boehringer Ingelheim Investigational Site
Toronto, Ontario, Canada
1245.25.20050 Boehringer Ingelheim Investigational Site
Gatineau, Quebec, Canada
1245.25.20043 Boehringer Ingelheim Investigational Site
Longueuil, Quebec, Canada
1245.25.20046 Boehringer Ingelheim Investigational Site
Longueuil, Quebec, Canada
1245.25.20041 Boehringer Ingelheim Investigational Site
Saskatoon, Saskatchewan, Canada
1245.25.57010 Boehringer Ingelheim Investigational Site
Armenia, Colombia
1245.25.57004 Boehringer Ingelheim Investigational Site
Barranquilla, Colombia
1245.25.57001 Boehringer Ingelheim Investigational Site
Bogotá, Colombia
1245.25.57003 Boehringer Ingelheim Investigational Site
Bogotá, Colombia
1245.25.57011 Boehringer Ingelheim Investigational Site
Bogotá, Colombia
1245.25.57006 Boehringer Ingelheim Investigational Site
Floridablanca, Colombia
1245.25.57009 Boehringer Ingelheim Investigational Site
Medellín, Colombia
1245.25.71005 Boehringer Ingelheim Investigational Site
Karlovac, Croatia
1245.25.71001 Boehringer Ingelheim Investigational Site
Krapinske Toplice, Croatia
1245.25.71006 Boehringer Ingelheim Investigational Site
Osijek, Croatia
1245.25.71003 Boehringer Ingelheim Investigational Site
Rijeka, Croatia
1245.25.71002 Boehringer Ingelheim Investigational Site
Zagreb, Croatia
1245.25.71004 Boehringer Ingelheim Investigational Site
Zagreb, Croatia
1245.25.42020 Boehringer Ingelheim Investigational Site
Brno, Czechia
1245.25.42018 Boehringer Ingelheim Investigational Site
Jindřichův Hradec, Czechia
1245.25.42015 Boehringer Ingelheim Investigational Site
Prague, Czechia
1245.25.42019 Boehringer Ingelheim Investigational Site
Ústí nad Labem, Czechia
1245.25.45007 Boehringer Ingelheim Investigational Site
Elsinore, Denmark
1245.25.45006 Boehringer Ingelheim Investigational Site
Frederiksberg, Denmark
1245.25.45003 Boehringer Ingelheim Investigational Site
Gentofte Municipality, Denmark
1245.25.45002 Boehringer Ingelheim Investigational Site
København NV, Denmark
1245.25.45004 Boehringer Ingelheim Investigational Site
Randers NØ, Denmark
1245.25.45005 Boehringer Ingelheim Investigational Site
Slagelse, Denmark
1245.25.37002 Boehringer Ingelheim Investigational Site
Tallinn, Estonia
1245.25.37003 Boehringer Ingelheim Investigational Site
Tallinn, Estonia
1245.25.37005 Boehringer Ingelheim Investigational Site
Tallinn, Estonia
1245.25.37001 Boehringer Ingelheim Investigational Site
Tartu, Estonia
1245.25.37004 Boehringer Ingelheim Investigational Site
Tartu, Estonia
1245.25.33022 Boehringer Ingelheim Investigational Site
Amiens, France
1245.25.33033 Boehringer Ingelheim Investigational Site
Angers, France
1245.25.33034 Boehringer Ingelheim Investigational Site
Angers, France
1245.25.33030 Boehringer Ingelheim Investigational Site
Bourg Des Cptes, France
1245.25.33023 Boehringer Ingelheim Investigational Site
Corbeil-Essonnes, France
1245.25.33024 Boehringer Ingelheim Investigational Site
Derval, France
1245.25.33029 Boehringer Ingelheim Investigational Site
Equeurdreville Haineville, France
1245.25.33027 Boehringer Ingelheim Investigational Site
Fleury-sur-Orne, France
1245.25.33021 Boehringer Ingelheim Investigational Site
Grenoble, France
1245.25.33003 Boehringer Ingelheim Investigational Site
La Rochelle, France
1245.25.33032 Boehringer Ingelheim Investigational Site
Le Creusot, France
1245.25.33004 Boehringer Ingelheim Investigational Site
Narbonne, France
1245.25.33047 Boehringer Ingelheim Investigational Site
Pessac, France
1245.25.33046 Boehringer Ingelheim Investigational Site
Poitiers, France
1245.25.33025 Boehringer Ingelheim Investigational Site
Saint Priez En Jarez, France
1245.25.33035 Boehringer Ingelheim Investigational Site
Tours, France
1245.25.99001 Boehringer Ingelheim Investigational Site
Batumi, Georgia
1245.25.99003 Boehringer Ingelheim Investigational Site
Kutaisi, Georgia
1245.25.99002 Boehringer Ingelheim Investigational Site
Tbilisi, Georgia
1245.25.99004 Boehringer Ingelheim Investigational Site
Tbilisi, Georgia
1245.25.99005 Boehringer Ingelheim Investigational Site
Tbilisi, Georgia
1245.25.99006 Boehringer Ingelheim Investigational Site
Tbilisi, Georgia
1245.25.99007 Boehringer Ingelheim Investigational Site
Tbilisi, Georgia
1245.25.99008 Boehringer Ingelheim Investigational Site
Tbilisi, Georgia
1245.25.30002 Boehringer Ingelheim Investigational Site
Athens, Greece
1245.25.30003 Boehringer Ingelheim Investigational Site
Athens, Greece
1245.25.30004 Boehringer Ingelheim Investigational Site
Athens, Greece
1245.25.30007 Boehringer Ingelheim Investigational Site
Athens, Greece
1245.25.30005 Boehringer Ingelheim Investigational Site
Larissa, Greece
1245.25.30001 Boehringer Ingelheim Investigational Site
Nikaia, Greece
1245.25.30006 Boehringer Ingelheim Investigational Site
Thessaloniki, Greece
1245.25.30008 Boehringer Ingelheim Investigational Site
Thessaloniki, Greece
1245.25.85201 Boehringer Ingelheim Investigational Site
Hong Kong, Hong Kong
1245.25.85205 Boehringer Ingelheim Investigational Site
Hong Kong, Hong Kong
1245.25.85207 Boehringer Ingelheim Investigational Site
Hong Kong, Hong Kong
1245.25.85208 Boehringer Ingelheim Investigational Site
Hong Kong, Hong Kong
1245.25.36002 Boehringer Ingelheim Investigational Site
Budapest, Hungary
1245.25.36004 Boehringer Ingelheim Investigational Site
Budapest, Hungary
1245.25.36008 Boehringer Ingelheim Investigational Site
Budapest, Hungary
1245.25.36006 Boehringer Ingelheim Investigational Site
Dunaújváros, Hungary
1245.25.36001 Boehringer Ingelheim Investigational Site
Gyula, Hungary
1245.25.36010 Boehringer Ingelheim Investigational Site
Kisvárda, Hungary
1245.25.36003 Boehringer Ingelheim Investigational Site
Szekszárd, Hungary
1245.25.36011 Boehringer Ingelheim Investigational Site
Szikszó, Hungary
1245.25.91307 Boehringer Ingelheim Investigational Site
Ahmedabad, India
1245.25.91302 Boehringer Ingelheim Investigational Site
Bangalore, India
1245.25.91317 Boehringer Ingelheim Investigational Site
Bangalore, India
1245.25.91319 Boehringer Ingelheim Investigational Site
Bangalore, India
1245.25.91320 Boehringer Ingelheim Investigational Site
Bangalore, India
1245.25.91303 Boehringer Ingelheim Investigational Site
Chennai, India
1245.25.91311 Boehringer Ingelheim Investigational Site
Hyderabad, India
1245.25.91318 Boehringer Ingelheim Investigational Site
Indore, India
1245.25.91305 Boehringer Ingelheim Investigational Site
Jaipur, India
1245.25.91309 Boehringer Ingelheim Investigational Site
Jalandhar, India
1245.25.91315 Boehringer Ingelheim Investigational Site
Kochi, India
1245.25.91313 Boehringer Ingelheim Investigational Site
Nagpur, India
1245.25.91324 Boehringer Ingelheim Investigational Site
Nagpur, India
1245.25.91301 Boehringer Ingelheim Investigational Site
Nashik, Maharashtra, India
1245.25.91308 Boehringer Ingelheim Investigational Site
Pune, India
1245.25.91316 Boehringer Ingelheim Investigational Site
Secunderabad, India
1245.25.91321 Boehringer Ingelheim Investigational Site
Varanasi, India
1245.25.91314 Boehringer Ingelheim Investigational Site
Vijaywada, India
1245.25.62006 Boehringer Ingelheim Investigational Site
Denpasar, Indonesia
1245.25.62009 Boehringer Ingelheim Investigational Site
Depok, Indonesia
1245.25.62002 Boehringer Ingelheim Investigational Site
Jakarta, Indonesia
1245.25.62008 Boehringer Ingelheim Investigational Site
Jakarta, Indonesia
1245.25.62010 Boehringer Ingelheim Investigational Site
Jakarta, Indonesia
1245.25.62004 Boehringer Ingelheim Investigational Site
Malang, Indonesia
1245.25.62003 Boehringer Ingelheim Investigational Site
Surabaya, Indonesia
1245.25.62001 Boehringer Ingelheim Investigational Site
Yogyakarta, Indonesia
1245.25.97003 Boehringer Ingelheim Investigational Site
Afula, Israel
1245.25.97006 Boehringer Ingelheim Investigational Site
Hadera, Israel
1245.25.97008 Boehringer Ingelheim Investigational Site
Haifa, Israel
1245.25.97009 Boehringer Ingelheim Investigational Site
Holon, Israel
1245.25.97005 Boehringer Ingelheim Investigational Site
Nahariya, Israel
1245.25.97001 Boehringer Ingelheim Investigational Site
Safed, Israel
1245.25.97002 Boehringer Ingelheim Investigational Site
Ẕerifin, Israel
1245.25.39007 Boehringer Ingelheim Investigational Site
Bologna, Italy
1245.25.39002 Boehringer Ingelheim Investigational Site
Campobasso, Italy
1245.25.39008 Boehringer Ingelheim Investigational Site
Catanzaro, Italy
1245.25.39010 Boehringer Ingelheim Investigational Site
Chieti, Italy
1245.25.39024 Boehringer Ingelheim Investigational Site
Ferrara, Italy
1245.25.39009 Boehringer Ingelheim Investigational Site
Florence, Italy
1245.25.39005 Boehringer Ingelheim Investigational Site
Foggia, Italy
1245.25.39004 Boehringer Ingelheim Investigational Site
Napoli, Italy
1245.25.39006 Boehringer Ingelheim Investigational Site
Padua, Italy
1245.25.39001 Boehringer Ingelheim Investigational Site
Pisa, Italy
1245.25.39003 Boehringer Ingelheim Investigational Site
Roma, Italy
1245.25.39011 Boehringer Ingelheim Investigational Site
Roma, Italy
1245.25.39012 Boehringer Ingelheim Investigational Site
Roma, Italy
1245.25.39014 Boehringer Ingelheim Investigational Site
Roma, Italy
1245.25.39013 Boehringer Ingelheim Investigational Site
Venezia, Italy
1245.25.81008 Boehringer Ingelheim Investigational Site
Chuo-ku, Tokyo, Japan
1245.25.81010 Boehringer Ingelheim Investigational Site
Gifushi, Gifu, Japan
1245.25.81002 Boehringer Ingelheim Investigational Site
Hanyushi, Saitama, Japan
1245.25.81013 Boehringer Ingelheim Investigational Site
Kamigyo-ku, Kyotoshi, Kyoto, Japan
1245.25.81003 Boehringer Ingelheim Investigational Site
Kishiwadashi. Osaka, Japan
1245.25.81012 Boehringer Ingelheim Investigational Site
Kita-ku, Nagoyashi, Aichi, Japan
1245.25.81014 Boehringer Ingelheim Investigational Site
Kumamoto-shi, Kumamoto, Japan
1245.25.81001 Boehringer Ingelheim Investigational Site
Matsudoshi, Chiba, Japan
1245.25.81006 Boehringer Ingelheim Investigational Site
Mitoshi, Ibaraki, Japan
1245.25.81005 Boehringer Ingelheim Investigational Site
Nishi-ku, Sapporoshi, Hokkaido, Japan
1245.25.81007 Boehringer Ingelheim Investigational Site
Nodashi, Chiba, Japan
1245.25.81004 Boehringer Ingelheim Investigational Site
Shimajiri-gun,Okinawa, Japan
1245.25.81009 Boehringer Ingelheim Investigational Site
Toyamashi, Toyama, Japan
1245.25.81015 Boehringer Ingelheim Investigational Site
Toyoakeshi, Aichi, Japan
1245.25.60019 Boehringer Ingelheim Investigational Site
Johor Bahru, Malaysia
1245.25.60020 Boehringer Ingelheim Investigational Site
Kedah, Malaysia
1245.25.60013 Boehringer Ingelheim Investigational Site
Kelantan, Malaysia
1245.25.60015 Boehringer Ingelheim Investigational Site
Kota Kinabalu, Malaysia
1245.25.60012 Boehringer Ingelheim Investigational Site
Kuala Lumpur, Malaysia
1245.25.60017 Boehringer Ingelheim Investigational Site
Kuala Lumpur, Malaysia
1245.25.60004 Boehringer Ingelheim Investigational Site
Kuala Pahang, Malaysia
1245.25.60016 Boehringer Ingelheim Investigational Site
Kuala Selangor, Malaysia
1245.25.60021 Boehringer Ingelheim Investigational Site
Kuala Selangor, Malaysia
1245.25.60018 Boehringer Ingelheim Investigational Site
Selangor Darul Ehsan, Malaysia
1245.25.52009 Boehringer Ingelheim Investigational Site
Colonia Americana, Mexico
1245.25.52007 Boehringer Ingelheim Investigational Site
Distrito Federal, Mexico
1245.25.52013 Boehringer Ingelheim Investigational Site
Ladrón de Guevara, Mexico
1245.25.52010 Boehringer Ingelheim Investigational Site
Los Robles, Mexico
1245.25.52001 Boehringer Ingelheim Investigational Site
Monterrey, Mexico
1245.25.52011 Boehringer Ingelheim Investigational Site
Reforma Social, Mexico
1245.25.52012 Boehringer Ingelheim Investigational Site
San Lucas Tepetlcalco, Mexico
1245.25.31015 Boehringer Ingelheim Investigational Site
Amersfoort, Netherlands
1245.25.31013 Boehringer Ingelheim Investigational Site
Apeldoorn, Netherlands
1245.25.31036 Boehringer Ingelheim Investigational Site
Baarle-Nassau, Netherlands
1245.25.31032 Boehringer Ingelheim Investigational Site
Delft, Netherlands
1245.25.31026 Boehringer Ingelheim Investigational Site
Den Helder, Netherlands
1245.25.31012 Boehringer Ingelheim Investigational Site
Geleen, Netherlands
1245.25.31017 Boehringer Ingelheim Investigational Site
Hardenberg, Netherlands
1245.25.31035 Boehringer Ingelheim Investigational Site
Heerlen, Netherlands
1245.25.31011 Boehringer Ingelheim Investigational Site
Hoogeveen, Netherlands
1245.25.31029 Boehringer Ingelheim Investigational Site
Hoogezand, Netherlands
1245.25.31023 Boehringer Ingelheim Investigational Site
Hoogwoud, Netherlands
1245.25.31009 Boehringer Ingelheim Investigational Site
Maastricht, Netherlands
1245.25.31031 Boehringer Ingelheim Investigational Site
Meppel, Netherlands
1245.25.31024 Boehringer Ingelheim Investigational Site
Nijverdal, Netherlands
1245.25.31014 Boehringer Ingelheim Investigational Site
Rotterdam, Netherlands
1245.25.31033 Boehringer Ingelheim Investigational Site
Rotterdam, Netherlands
1245.25.31030 Boehringer Ingelheim Investigational Site
Schiedam, Netherlands
1245.25.31002 Boehringer Ingelheim Investigational Site
Utrecht, Netherlands
1245.25.31028 Boehringer Ingelheim Investigational Site
Wildervank, Netherlands
1245.25.31034 Boehringer Ingelheim Investigational Site
Zutphen, Netherlands
1245.25.64004 Boehringer Ingelheim Investigational Site
Christchurch, New Zealand
1245.25.64001 Boehringer Ingelheim Investigational Site
Grafton / Auckland, New Zealand
1245.25.64003 Boehringer Ingelheim Investigational Site
Wellington, New Zealand
1245.25.47002 Boehringer Ingelheim Investigational Site
Fornebu, Norway
1245.25.47004 Boehringer Ingelheim Investigational Site
Gjøvik, Norway
1245.25.47009 Boehringer Ingelheim Investigational Site
Kløfta, Norway
1245.25.47008 Boehringer Ingelheim Investigational Site
Kongsvinger, Norway
1245.25.47001 Boehringer Ingelheim Investigational Site
Oslo, Norway
1245.25.47006 Boehringer Ingelheim Investigational Site
Oslo, Norway
1245.25.47007 Boehringer Ingelheim Investigational Site
Trondheim, Norway
1245.25.47005 Boehringer Ingelheim Investigational Site
Tynset, Norway
1245.25.51001 Boehringer Ingelheim Investigational Site
Arequipa, Peru
1245.25.51008 Boehringer Ingelheim Investigational Site
Arequipa, Peru
1245.25.51002 Boehringer Ingelheim Investigational Site
Bellavista, Peru
1245.25.51004 Boehringer Ingelheim Investigational Site
El Agustino, Peru
1245.25.51006 Boehringer Ingelheim Investigational Site
Ica, Peru
1245.25.51003 Boehringer Ingelheim Investigational Site
Jesus Maria, Peru
1245.25.51007 Boehringer Ingelheim Investigational Site
Lima, Peru
1245.25.51009 Boehringer Ingelheim Investigational Site
Lima, Peru
1245.25.51010 Boehringer Ingelheim Investigational Site
Lima, Peru
1245.25.51011 Boehringer Ingelheim Investigational Site
Lima, Peru
1245.25.51005 Boehringer Ingelheim Investigational Site
Miraflores, Peru
1245.25.63016 Boehringer Ingelheim Investigational Site
Cavite City, Philippines
1245.25.63002 Boehringer Ingelheim Investigational Site
Cebu, Philippines
1245.25.63003 Boehringer Ingelheim Investigational Site
Davao City, Philippines
1245.25.63020 Boehringer Ingelheim Investigational Site
Jaro Iloilo City, Philippines
1245.25.63001 Boehringer Ingelheim Investigational Site
Manila, Philippines
1245.25.63004 Boehringer Ingelheim Investigational Site
Manila, Philippines
1245.25.63018 Boehringer Ingelheim Investigational Site
Manila, Philippines
1245.25.63009 Boehringer Ingelheim Investigational Site
Marikina City, Philippines
1245.25.63021 Boehringer Ingelheim Investigational Site
Marikina City, Philippines
1245.25.63019 Boehringer Ingelheim Investigational Site
Tarlac City, Philippines
1245.25.48013 Boehringer Ingelheim Investigational Site
Gdansk, Poland
1245.25.48004 Boehringer Ingelheim Investigational Site
Lodz, Poland
1245.25.48009 Boehringer Ingelheim Investigational Site
Lodz, Poland
1245.25.48010 Boehringer Ingelheim Investigational Site
Lodz, Poland
1245.25.48001 Boehringer Ingelheim Investigational Site
Lublin, Poland
1245.25.48014 Boehringer Ingelheim Investigational Site
Oświęcim, Poland
1245.25.48002 Boehringer Ingelheim Investigational Site
Poznan, Poland
1245.25.48008 Boehringer Ingelheim Investigational Site
Puławy, Poland
1245.25.48007 Boehringer Ingelheim Investigational Site
Ruda Śląska, Poland
1245.25.48005 Boehringer Ingelheim Investigational Site
Torun, Poland
1245.25.48011 Boehringer Ingelheim Investigational Site
Torun, Poland
1245.25.35006 Boehringer Ingelheim Investigational Site
Amadora, Portugal
1245.25.35004 Boehringer Ingelheim Investigational Site
Coimbra, Portugal
1245.25.35018 Boehringer Ingelheim Investigational Site
Faro, Portugal
1245.25.35021 Boehringer Ingelheim Investigational Site
Funchal, Portugal
1245.25.35008 Boehringer Ingelheim Investigational Site
Leiria, Portugal
1245.25.35001 Boehringer Ingelheim Investigational Site
Lisbon, Portugal
1245.25.35002 Boehringer Ingelheim Investigational Site
Lisbon, Portugal
1245.25.35015 Boehringer Ingelheim Investigational Site
Lisbon, Portugal
1245.25.35017 Boehringer Ingelheim Investigational Site
Lisbon, Portugal
1245.25.35011 Boehringer Ingelheim Investigational Site
Porto, Portugal
1245.25.35005 Boehringer Ingelheim Investigational Site
Santiago do Cacém, Portugal
1245.25.35020 Boehringer Ingelheim Investigational Site
Torres Novas, Portugal
1245.25.35014 Boehringer Ingelheim Investigational Site
Viana do Castelo, Portugal
1245.25.35019 Boehringer Ingelheim Investigational Site
Vila Nova de Gaia, Portugal
1245.25.40008 Boehringer Ingelheim Investigational Site
Alba Iulia, Romania
1245.25.40011 Boehringer Ingelheim Investigational Site
Baia Mare Maramures, Romania
1245.25.40003 Boehringer Ingelheim Investigational Site
Bucharest, Romania
1245.25.40007 Boehringer Ingelheim Investigational Site
Bucharest, Romania
1245.25.40005 Boehringer Ingelheim Investigational Site
Constanța, Romania
1245.25.40002 Boehringer Ingelheim Investigational Site
Craiova, Romania
1245.25.40006 Boehringer Ingelheim Investigational Site
Craiova, Romania
1245.25.40009 Boehringer Ingelheim Investigational Site
Oradea, Romania
1245.25.40010 Boehringer Ingelheim Investigational Site
Târgu Mureş, Romania
1245.25.70019 Boehringer Ingelheim Investigational Site
Barnaul, Russia
1245.25.70015 Boehringer Ingelheim Investigational Site
Kemerovo, Russia
1245.25.70020 Boehringer Ingelheim Investigational Site
Kemerovo, Russia
1245.25.70003 Boehringer Ingelheim Investigational Site
Moscow, Russia
1245.25.70009 Boehringer Ingelheim Investigational Site
Moscow, Russia
1245.25.70011 Boehringer Ingelheim Investigational Site
Moscow, Russia
1245.25.70016 Boehringer Ingelheim Investigational Site
Moscow, Russia
1245.25.70021 Boehringer Ingelheim Investigational Site
Moscow, Russia
1245.25.70022 Boehringer Ingelheim Investigational Site
Moscow, Russia
1245.25.70014 Boehringer Ingelheim Investigational Site
Novosibirsk, Russia
1245.25.70018 Boehringer Ingelheim Investigational Site
Novosibirsk, Russia
1245.25.70024 Boehringer Ingelheim Investigational Site
Novosibirsk, Russia
1245.25.70028 Boehringer Ingelheim Investigational Site
Novosibirsk, Russia
1245.25.70001 Boehringer Ingelheim Investigational Site
Saint Petersburg, Russia
1245.25.70004 Boehringer Ingelheim Investigational Site
Saint Petersburg, Russia
1245.25.70005 Boehringer Ingelheim Investigational Site
Saint Petersburg, Russia
1245.25.70006 Boehringer Ingelheim Investigational Site
Saint Petersburg, Russia
1245.25.70013 Boehringer Ingelheim Investigational Site
Saint Petersburg, Russia
1245.25.70017 Boehringer Ingelheim Investigational Site
Saint Petersburg, Russia
1245.25.70023 Boehringer Ingelheim Investigational Site
Saint Petersburg, Russia
1245.25.70025 Boehringer Ingelheim Investigational Site
Saint Petersburg, Russia
1245.25.70026 Boehringer Ingelheim Investigational Site
Saint Petersburg, Russia
1245.25.70027 Boehringer Ingelheim Investigational Site
Saint Petersburg, Russia
1245.25.70002 Boehringer Ingelheim Investigational Site
Vsevolozhsk, Russia
1245.25.70029 Boehringer Ingelheim Investigational Site
Yaroslavl, Russia
1245.25.65001 Boehringer Ingelheim Investigational Site
Singapore, Singapore
1245.25.65003 Boehringer Ingelheim Investigational Site
Singapore, Singapore
1245.25.65004 Boehringer Ingelheim Investigational Site
Singapore, Singapore
1245.25.76007 Boehringer Ingelheim Investigational Site
Alberton, South Africa
1245.25.76002 Boehringer Ingelheim Investigational Site
Bellville, South Africa
1245.25.76009 Boehringer Ingelheim Investigational Site
Bloemfontein, South Africa
1245.25.76014 Boehringer Ingelheim Investigational Site
Cape Town, South Africa
1245.25.76020 Boehringer Ingelheim Investigational Site
Cape Town, South Africa
1245.25.76022 Boehringer Ingelheim Investigational Site
Chatsworth Unit 10, South Africa
1245.25.76013 Boehringer Ingelheim Investigational Site
Durban, South Africa
1245.25.76016 Boehringer Ingelheim Investigational Site
Durban, South Africa
1245.25.76019 Boehringer Ingelheim Investigational Site
Durban, South Africa
1245.25.76003 Boehringer Ingelheim Investigational Site
Goodwood, South Africa
1245.25.76001 Boehringer Ingelheim Investigational Site
Houghton Estate, South Africa
1245.25.76021 Boehringer Ingelheim Investigational Site
Kempton Park, South Africa
1245.25.76017 Boehringer Ingelheim Investigational Site
Krugersdorp, South Africa
1245.25.76004 Boehringer Ingelheim Investigational Site
Newtown, South Africa
1245.25.76006 Boehringer Ingelheim Investigational Site
Paarl, South Africa
1245.25.76005 Boehringer Ingelheim Investigational Site
Parow, South Africa
1245.25.76018 Boehringer Ingelheim Investigational Site
Port Elizabeth, South Africa
1245.25.76015 Boehringer Ingelheim Investigational Site
Somerset West, South Africa
1245.25.76012 Boehringer Ingelheim Investigational Site
Sydenham, South Africa
1245.25.76008 Boehringer Ingelheim Investigational Site
Tongaat, South Africa
1245.25.76023 Boehringer Ingelheim Investigational Site
Worcester, South Africa
1245.25.82030 Boehringer Ingelheim Investigational Site
Busan, South Korea
1245.25.82018 Boehringer Ingelheim Investigational Site
Daegu, South Korea
1245.25.82021 Boehringer Ingelheim Investigational Site
Daejeon, South Korea
1245.25.82031 Boehringer Ingelheim Investigational Site
Daejoen, South Korea
1245.25.82027 Boehringer Ingelheim Investigational Site
Goyang, South Korea
1245.25.82022 Boehringer Ingelheim Investigational Site
Gwangju, South Korea
1245.25.82029 Boehringer Ingelheim Investigational Site
Incheon, South Korea
1245.25.82017 Boehringer Ingelheim Investigational Site
Pusan, South Korea
1245.25.82015 Boehringer Ingelheim Investigational Site
Seoul, South Korea
1245.25.82016 Boehringer Ingelheim Investigational Site
Seoul, South Korea
1245.25.82019 Boehringer Ingelheim Investigational Site
Seoul, South Korea
1245.25.82020 Boehringer Ingelheim Investigational Site
Seoul, South Korea
1245.25.82023 Boehringer Ingelheim Investigational Site
Seoul, South Korea
1245.25.82024 Boehringer Ingelheim Investigational Site
Seoul, South Korea
1245.25.82025 Boehringer Ingelheim Investigational Site
Seoul, South Korea
1245.25.82026 Boehringer Ingelheim Investigational Site
Suwon, South Korea
1245.25.82028 Boehringer Ingelheim Investigational Site
Wŏnju, South Korea
1245.25.34025 Boehringer Ingelheim Investigational Site
Alcorcon (Madrid), Spain
1245.25.34048 Boehringer Ingelheim Investigational Site
Alicante, Spain
1245.25.34050 Boehringer Ingelheim Investigational Site
Alzira, Spain
1245.25.34039 Boehringer Ingelheim Investigational Site
Ávila, Spain
1245.25.34040 Boehringer Ingelheim Investigational Site
Badía Del Vallès - Barcelona, Spain
1245.25.34029 Boehringer Ingelheim Investigational Site
Barcelona, Spain
1245.25.34030 Boehringer Ingelheim Investigational Site
Barcelona, Spain
1245.25.34049 Boehringer Ingelheim Investigational Site
Barcelona, Spain
1245.25.34031 Boehringer Ingelheim Investigational Site
Granada, Spain
1245.25.34024 Boehringer Ingelheim Investigational Site
Leganes (Madrid), Spain
1245.25.34013 Boehringer Ingelheim Investigational Site
Madrid, Spain
1245.25.34023 Boehringer Ingelheim Investigational Site
Madrid, Spain
1245.25.34026 Boehringer Ingelheim Investigational Site
Madrid, Spain
1245.25.34028 Boehringer Ingelheim Investigational Site
Madrid, Spain
1245.25.34033 Boehringer Ingelheim Investigational Site
Madrid, Spain
1245.25.34036 Boehringer Ingelheim Investigational Site
Madrid, Spain
1245.25.34038 Boehringer Ingelheim Investigational Site
Madrid, Spain
1245.25.34022 Boehringer Ingelheim Investigational Site
Mahadahonda (Madrid), Spain
1245.25.34047 Boehringer Ingelheim Investigational Site
Palma de Mallorca, Spain
1245.25.34034 Boehringer Ingelheim Investigational Site
Sabadell (Barcelona), Spain
1245.25.34027 Boehringer Ingelheim Investigational Site
Salamanca, Spain
1245.25.34037 Boehringer Ingelheim Investigational Site
Santa Cruz de Tenerife, Spain
1245.25.34046 Boehringer Ingelheim Investigational Site
Segovia, Spain
1245.25.94002 Boehringer Ingelheim Investigational Site
Colombo, Sri Lanka
1245.25.94005 Boehringer Ingelheim Investigational Site
Kalubowila, Sri Lanka
1245.25.94004 Boehringer Ingelheim Investigational Site
Kandy, Sri Lanka
1245.25.94006 Boehringer Ingelheim Investigational Site
Kandy, Sri Lanka
1245.25.94001 Boehringer Ingelheim Investigational Site
Nugegoda, Sri Lanka
1245.25.94003 Boehringer Ingelheim Investigational Site
Ragama, Sri Lanka
1245.25.88022 Boehringer Ingelheim Investigational Site
Hualien City, Taiwan
1245.25.88010 Boehringer Ingelheim Investigational Site
Kaohsiung City, Taiwan
1245.25.88019 Boehringer Ingelheim Investigational Site
Kaohsiung City, Taiwan
1245.25.88009 Boehringer Ingelheim Investigational Site
Taichung, Taiwan
1245.25.88020 Boehringer Ingelheim Investigational Site
Taichung, Taiwan
1245.25.88018 Boehringer Ingelheim Investigational Site
Tainan, Taiwan
1245.25.88015 Boehringer Ingelheim Investigational Site
Taipei, Taiwan
1245.25.88016 Boehringer Ingelheim Investigational Site
Taipei, Taiwan
1245.25.88023 Boehringer Ingelheim Investigational Site
Tamsui, Taipei County, Taiwan
1245.25.88017 Boehringer Ingelheim Investigational Site
Taoyuan District, Taiwan
1245.25.66006 Boehringer Ingelheim Investigational Site
Bangkok, Thailand
1245.25.66007 Boehringer Ingelheim Investigational Site
Bangkok, Thailand
1245.25.66009 Boehringer Ingelheim Investigational Site
Chiang Mai, Thailand
1245.25.66004 Boehringer Ingelheim Investigational Site
Muang District, Thailand
1245.25.66010 Boehringer Ingelheim Investigational Site
Nakhonratchasima, Thailand
1245.25.66011 Boehringer Ingelheim Investigational Site
Pathum Tani, Thailand
1245.25.75001 Boehringer Ingelheim Investigational Site
Kharkiv, Ukraine
1245.25.75008 Boehringer Ingelheim Investigational Site
Kharkiv, Ukraine
1245.25.75009 Boehringer Ingelheim Investigational Site
Kharkiv, Ukraine
1245.25.75011 Boehringer Ingelheim Investigational Site
Kharkiv, Ukraine
1245.25.75007 Boehringer Ingelheim Investigational Site
Kiev, Ukraine
1245.25.75012 Boehringer Ingelheim Investigational Site
Kiev, Ukraine
1245.25.75010 Boehringer Ingelheim Investigational Site
Odesa, Ukraine
1245.25.44045 Boehringer Ingelheim Investigational Site
Airdrie, United Kingdom
1245.25.44020 Boehringer Ingelheim Investigational Site
Ashford, United Kingdom
1245.25.44013 Boehringer Ingelheim Investigational Site
Blackpool, United Kingdom
1245.25.44014 Boehringer Ingelheim Investigational Site
Bolton, United Kingdom
1245.25.44021 Boehringer Ingelheim Investigational Site
Bradford-on-Avon, United Kingdom
1245.25.44002 Boehringer Ingelheim Investigational Site
Dumfries, United Kingdom
1245.25.44009 Boehringer Ingelheim Investigational Site
Dundee, United Kingdom
1245.25.44005 Boehringer Ingelheim Investigational Site
Edinburgh, United Kingdom
1245.25.44004 Boehringer Ingelheim Investigational Site
Fowey, United Kingdom
1245.25.44001 Boehringer Ingelheim Investigational Site
Frome, United Kingdom
1245.25.44003 Boehringer Ingelheim Investigational Site
Inverness, United Kingdom
1245.25.44044 Boehringer Ingelheim Investigational Site
Wishaw, United Kingdom
Related Publications (39)
Odutayo A, Zinman B, Wanner C, Zwiener I, Lund SS, Hantel S, Fitchett D, Udell JA; EMPA-REG OUTCOME Trial Investigators. Effect of Qualifying Atherosclerotic Cardiovascular Disease Diagnosis Proximity on Cardiovascular Risk and Benefit of Empagliflozin in the EMPA-REG OUTCOME Trial. CJC Open. 2024 Feb 9;6(7):868-875. doi: 10.1016/j.cjco.2024.01.013. eCollection 2024 Jul.
PMID: 39026628DERIVEDFitchett D, Zinman B, Inzucchi SE, Wanner C, Anker SD, Pocock S, Mattheus M, Vedin O, Lund SS. Effect of empagliflozin on total myocardial infarction events by type and additional coronary outcomes: insights from the randomized EMPA-REG OUTCOME trial. Cardiovasc Diabetol. 2024 Jul 11;23(1):248. doi: 10.1186/s12933-024-02328-6.
PMID: 38992713DERIVEDNatale P, Tunnicliffe DJ, Toyama T, Palmer SC, Saglimbene VM, Ruospo M, Gargano L, Stallone G, Gesualdo L, Strippoli GF. Sodium-glucose co-transporter protein 2 (SGLT2) inhibitors for people with chronic kidney disease and diabetes. Cochrane Database Syst Rev. 2024 May 21;5(5):CD015588. doi: 10.1002/14651858.CD015588.pub2.
PMID: 38770818DERIVEDHadjadj S, Cooper ME, Steubl D, Petrini M, Hantel S, Mattheus M, Wanner C, Thomas MC. Empagliflozin and Rapid Kidney Function Decline Incidence in Type 2 Diabetes: An Exploratory Analysis From the EMPA-REG OUTCOME Trial. Kidney Med. 2023 Dec 18;6(3):100783. doi: 10.1016/j.xkme.2023.100783. eCollection 2024 Mar.
PMID: 38419787DERIVEDBalasubramanian P, Kernan WN, Sheth KN, Ofstad AP, Rosenstock J, Wanner C, Zinman B, Mattheus M, Marx N, Inzucchi SE. Baseline Cardiovascular Risk Factor Control in Patients With Type 2 Diabetes and Coronary Disease Versus Stroke: Secondary Analysis of Cardiovascular Outcome Trials. Stroke. 2023 Aug;54(8):2013-2021. doi: 10.1161/STROKEAHA.122.042053. Epub 2023 Jul 14.
PMID: 37449424DERIVEDDar MS, Wanner C, Marx N, Ofstad AP, Mattheus M, Kaspers S, Beg SA. Cardiovascular outcomes trial data from EMPA-REG OUTCOME, CAROLINA and CARMELINA: Assessment of a novel staging system for type 2 diabetes. Diabetes Obes Metab. 2023 May;25(5):1372-1384. doi: 10.1111/dom.14989. Epub 2023 Mar 6.
PMID: 36700391DERIVEDTuttle KR, Levin A, Nangaku M, Kadowaki T, Agarwal R, Hauske SJ, Elsasser A, Ritter I, Steubl D, Wanner C, Wheeler DC. Safety of Empagliflozin in Patients With Type 2 Diabetes and Chronic Kidney Disease: Pooled Analysis of Placebo-Controlled Clinical Trials. Diabetes Care. 2022 Jun 2;45(6):1445-1452. doi: 10.2337/dc21-2034.
PMID: 35472672DERIVEDKahl S, Ofstad AP, Zinman B, Wanner C, Schuler E, Sattar N, Inzucchi SE, Roden M. Effects of empagliflozin on markers of liver steatosis and fibrosis and their relationship to cardiorenal outcomes. Diabetes Obes Metab. 2022 Jun;24(6):1061-1071. doi: 10.1111/dom.14670. Epub 2022 Mar 8.
PMID: 35166009DERIVEDRuggenenti P, Kraus BJ, Inzucchi SE, Zinman B, Hantel S, Mattheus M, von Eynatten M, Remuzzi G, Koitka-Weber A, Wanner C. Nephrotic-range proteinuria in type 2 diabetes: Effects of empagliflozin on kidney disease progression and clinical outcomes. EClinicalMedicine. 2021 Dec 24;43:101240. doi: 10.1016/j.eclinm.2021.101240. eCollection 2022 Jan.
PMID: 35005582DERIVEDReifsnider OS, Kansal AR, Wanner C, Pfarr E, Koitka-Weber A, Brand SB, Stargardter M, Wang C, Kuti E, Ustyugova A. Cost-Effectiveness of Empagliflozin in Patients With Diabetic Kidney Disease in the United States: Findings Based on the EMPA-REG OUTCOME Trial. Am J Kidney Dis. 2022 Jun;79(6):796-806. doi: 10.1053/j.ajkd.2021.09.014. Epub 2021 Nov 6.
PMID: 34752913DERIVEDFerreira JP, Inzucchi SE, Mattheus M, Meinicke T, Steubl D, Wanner C, Zinman B. Empagliflozin and uric acid metabolism in diabetes: A post hoc analysis of the EMPA-REG OUTCOME trial. Diabetes Obes Metab. 2022 Jan;24(1):135-141. doi: 10.1111/dom.14559. Epub 2021 Oct 4.
PMID: 34558768DERIVEDVaduganathan M, Inzucchi SE, Sattar N, Fitchett DH, Ofstad AP, Brueckmann M, George JT, Verma S, Mattheus M, Wanner C, Zinman B, Butler J. Effects of empagliflozin on insulin initiation or intensification in patients with type 2 diabetes and cardiovascular disease: Findings from the EMPA-REG OUTCOME trial. Diabetes Obes Metab. 2021 Dec;23(12):2775-2784. doi: 10.1111/dom.14535. Epub 2021 Oct 7.
PMID: 34463409DERIVEDSharma A, Ofstad AP, Ahmad T, Zinman B, Zwiener I, Fitchett D, Wanner C, George JT, Hantel S, Desai N, Mentz RJ. Patient Phenotypes and SGLT-2 Inhibition in Type 2 Diabetes: Insights From the EMPA-REG OUTCOME Trial. JACC Heart Fail. 2021 Aug;9(8):568-577. doi: 10.1016/j.jchf.2021.03.003.
PMID: 34325887DERIVEDCherney DZI, Dagogo-Jack S, McGuire DK, Cosentino F, Pratley R, Shih WJ, Frederich R, Maldonado M, Liu J, Wang S, Cannon CP; VERTIS CV Investigators. Kidney outcomes using a sustained >/=40% decline in eGFR: A meta-analysis of SGLT2 inhibitor trials. Clin Cardiol. 2021 Aug;44(8):1139-1143. doi: 10.1002/clc.23665. Epub 2021 Jun 15.
PMID: 34129237DERIVEDFerreira JP, Kraus BJ, Zwiener I, Lauer S, Zinman B, Fitchett DH, Koitka-Weber A, George JT, Ofstad AP, Wanner C, Zannad F. Cardio/Kidney Composite End Points: A Post Hoc Analysis of the EMPA-REG OUTCOME Trial. J Am Heart Assoc. 2021 Apr 6;10(7):e020053. doi: 10.1161/JAHA.120.020053. Epub 2021 Mar 23.
PMID: 33754809DERIVEDFerreira JP, Verma S, Fitchett D, Ofstad AP, Lauer S, Zwiener I, George J, Wanner C, Zinman B, Inzucchi SE. Metabolic syndrome in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a post hoc analyses of the EMPA-REG OUTCOME trial. Cardiovasc Diabetol. 2020 Nov 26;19(1):200. doi: 10.1186/s12933-020-01174-6.
PMID: 33243221DERIVEDMcGuire DK, Zinman B, Inzucchi SE, Wanner C, Fitchett D, Anker SD, Pocock S, Kaspers S, George JT, von Eynatten M, Johansen OE, Jamal W, Mattheus M, Elsasser U, Hantel S, Lund SS. Effects of empagliflozin on first and recurrent clinical events in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a secondary analysis of the EMPA-REG OUTCOME trial. Lancet Diabetes Endocrinol. 2020 Dec;8(12):949-959. doi: 10.1016/S2213-8587(20)30344-2.
PMID: 33217335DERIVEDCeriello A, Ofstad AP, Zwiener I, Kaspers S, George J, Nicolucci A. Empagliflozin reduced long-term HbA1c variability and cardiovascular death: insights from the EMPA-REG OUTCOME trial. Cardiovasc Diabetol. 2020 Oct 13;19(1):176. doi: 10.1186/s12933-020-01147-9.
PMID: 33050931DERIVEDNeeland IJ, Eliasson B, Kasai T, Marx N, Zinman B, Inzucchi SE, Wanner C, Zwiener I, Wojeck BS, Yaggi HK, Johansen OE; EMPA-REG OUTCOME Investigators. The Impact of Empagliflozin on Obstructive Sleep Apnea and Cardiovascular and Renal Outcomes: An Exploratory Analysis of the EMPA-REG OUTCOME Trial. Diabetes Care. 2020 Dec;43(12):3007-3015. doi: 10.2337/dc20-1096. Epub 2020 Oct 1.
PMID: 33004464DERIVEDLevin A, Perkovic V, Wheeler DC, Hantel S, George JT, von Eynatten M, Koitka-Weber A, Wanner C; EMPA-REG OUTCOME Investigators. Empagliflozin and Cardiovascular and Kidney Outcomes across KDIGO Risk Categories: Post Hoc Analysis of a Randomized, Double-Blind, Placebo-Controlled, Multinational Trial. Clin J Am Soc Nephrol. 2020 Oct 7;15(10):1433-1444. doi: 10.2215/CJN.14901219. Epub 2020 Sep 29.
PMID: 32994159DERIVEDWaijer SW, Xie D, Inzucchi SE, Zinman B, Koitka-Weber A, Mattheus M, von Eynatten M, Inker LA, Wanner C, Heerspink HJL. Short-Term Changes in Albuminuria and Risk of Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus: A Post Hoc Analysis of the EMPA-REG OUTCOME Trial. J Am Heart Assoc. 2020 Sep 15;9(18):e016976. doi: 10.1161/JAHA.120.016976. Epub 2020 Sep 6.
PMID: 32893717DERIVEDBohm M, Fitchett D, Ofstad AP, Brueckmann M, Kaspers S, George JT, Zwiener I, Zinman B, Wanner C, Marx N, Mancia G, Anker SD, Mahfoud F. Heart failure and renal outcomes according to baseline and achieved blood pressure in patients with type 2 diabetes: results from EMPA-REG OUTCOME. J Hypertens. 2020 Sep;38(9):1829-1840. doi: 10.1097/HJH.0000000000002492.
PMID: 32618884DERIVEDInzucchi SE, Khunti K, Fitchett DH, Wanner C, Mattheus M, George JT, Ofstad AP, Zinman B. Cardiovascular Benefit of Empagliflozin Across the Spectrum of Cardiovascular Risk Factor Control in the EMPA-REG OUTCOME Trial. J Clin Endocrinol Metab. 2020 Sep 1;105(9):3025-35. doi: 10.1210/clinem/dgaa321.
PMID: 32485734DERIVEDFerreira JP, Fitchett D, Ofstad AP, Kraus BJ, Wanner C, Zwiener I, Zinman B, Lauer S, George JT, Rossignol P, Zannad F. Empagliflozin for Patients With Presumed Resistant Hypertension: A Post Hoc Analysis of the EMPA-REG OUTCOME Trial. Am J Hypertens. 2020 Dec 31;33(12):1092-1101. doi: 10.1093/ajh/hpaa073.
PMID: 32369546DERIVEDPerkovic V, Koitka-Weber A, Cooper ME, Schernthaner G, Pfarr E, Woerle HJ, von Eynatten M, Wanner C. Choice of endpoint in kidney outcome trials: considerations from the EMPA-REG OUTCOME(R) trial. Nephrol Dial Transplant. 2020 Dec 4;35(12):2103-2111. doi: 10.1093/ndt/gfz179.
PMID: 31495881DERIVEDKansal A, Reifsnider OS, Proskorovsky I, Zheng Y, Pfarr E, George JT, Kandaswamy P, Ruffolo A. Cost-effectiveness analysis of empagliflozin treatment in people with Type 2 diabetes and established cardiovascular disease in the EMPA-REG OUTCOME trial. Diabet Med. 2019 Nov;36(11):1494-1502. doi: 10.1111/dme.14076. Epub 2019 Jul 23.
PMID: 31295358DERIVEDButler J, Zannad F, Fitchett D, Zinman B, Koitka-Weber A, von Eynatten M, Zwiener I, George J, Brueckmann M, Cheung AK, Wanner C. Empagliflozin Improves Kidney Outcomes in Patients With or Without Heart Failure. Circ Heart Fail. 2019 Jun;12(6):e005875. doi: 10.1161/CIRCHEARTFAILURE.118.005875. Epub 2019 Jun 5.
PMID: 31163986DERIVEDVerma S, Wanner C, Zwiener I, Ofstad AP, George JT, Fitchett D, Zinman B; EMPA-REG OUTCOME Investigators. Influence of Microvascular Disease on Cardiovascular Events in Type 2 Diabetes. J Am Coll Cardiol. 2019 Jun 4;73(21):2780-2782. doi: 10.1016/j.jacc.2019.03.002. Epub 2019 Mar 15. No abstract available.
PMID: 30885684DERIVEDJanuzzi J, Ferreira JP, Bohm M, Kaul S, Wanner C, Brueckmann M, Petrie MC, Ofstad AP, Zeller C, George J, Fitchett D, Zannad F. Empagliflozin reduces the risk of a broad spectrum of heart failure outcomes regardless of heart failure status at baseline. Eur J Heart Fail. 2019 Mar;21(3):386-388. doi: 10.1002/ejhf.1419. Epub 2019 Feb 14. No abstract available.
PMID: 30767353DERIVEDFitchett D, Inzucchi SE, Cannon CP, McGuire DK, Scirica BM, Johansen OE, Sambevski S, Kaspers S, Pfarr E, George JT, Zinman B. Empagliflozin Reduced Mortality and Hospitalization for Heart Failure Across the Spectrum of Cardiovascular Risk in the EMPA-REG OUTCOME Trial. Circulation. 2019 Mar 12;139(11):1384-1395. doi: 10.1161/CIRCULATIONAHA.118.037778.
PMID: 30586757DERIVEDVerma S, Mazer CD, Fitchett D, Inzucchi SE, Pfarr E, George JT, Zinman B. Empagliflozin reduces cardiovascular events, mortality and renal events in participants with type 2 diabetes after coronary artery bypass graft surgery: subanalysis of the EMPA-REG OUTCOME(R) randomised trial. Diabetologia. 2018 Aug;61(8):1712-1723. doi: 10.1007/s00125-018-4644-9. Epub 2018 May 19.
PMID: 29777264DERIVEDWittbrodt ET, Eudicone JM, Bell KF, Enhoffer DM, Latham K, Green JB. Eligibility varies among the 4 sodium-glucose cotransporter-2 inhibitor cardiovascular outcomes trials: implications for the general type 2 diabetes US population. Am J Manag Care. 2018 Apr;24(8 Suppl):S138-S145.
PMID: 29693360DERIVEDInzucchi SE, Zinman B, Fitchett D, Wanner C, Ferrannini E, Schumacher M, Schmoor C, Ohneberg K, Johansen OE, George JT, Hantel S, Bluhmki E, Lachin JM. How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial. Diabetes Care. 2018 Feb;41(2):356-363. doi: 10.2337/dc17-1096. Epub 2017 Dec 4.
PMID: 29203583DERIVEDWanner C, Lachin JM, Inzucchi SE, Fitchett D, Mattheus M, George J, Woerle HJ, Broedl UC, von Eynatten M, Zinman B; EMPA-REG OUTCOME Investigators. Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease. Circulation. 2018 Jan 9;137(2):119-129. doi: 10.1161/CIRCULATIONAHA.117.028268. Epub 2017 Sep 13.
PMID: 28904068DERIVEDCherney DZI, Zinman B, Inzucchi SE, Koitka-Weber A, Mattheus M, von Eynatten M, Wanner C. Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial. Lancet Diabetes Endocrinol. 2017 Aug;5(8):610-621. doi: 10.1016/S2213-8587(17)30182-1. Epub 2017 Jun 27.
PMID: 28666775DERIVEDZinman B, Inzucchi SE, Lachin JM, Wanner C, Fitchett D, Kohler S, Mattheus M, Woerle HJ, Broedl UC, Johansen OE, Albers GW, Diener HC; EMPA-REG OUTCOME Investigators (Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients). Empagliflozin and Cerebrovascular Events in Patients With Type 2 Diabetes Mellitus at High Cardiovascular Risk. Stroke. 2017 May;48(5):1218-1225. doi: 10.1161/STROKEAHA.116.015756. Epub 2017 Apr 6.
PMID: 28386035DERIVEDWanner C, Inzucchi SE, Lachin JM, Fitchett D, von Eynatten M, Mattheus M, Johansen OE, Woerle HJ, Broedl UC, Zinman B; EMPA-REG OUTCOME Investigators. Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. N Engl J Med. 2016 Jul 28;375(4):323-34. doi: 10.1056/NEJMoa1515920. Epub 2016 Jun 14.
PMID: 27299675DERIVEDZinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE; EMPA-REG OUTCOME Investigators. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015 Nov 26;373(22):2117-28. doi: 10.1056/NEJMoa1504720. Epub 2015 Sep 17.
PMID: 26378978DERIVEDZinman B, Inzucchi SE, Lachin JM, Wanner C, Ferrari R, Fitchett D, Bluhmki E, Hantel S, Kempthorne-Rawson J, Newman J, Johansen OE, Woerle HJ, Broedl UC. Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME). Cardiovasc Diabetol. 2014 Jun 19;13:102. doi: 10.1186/1475-2840-13-102.
PMID: 24943000DERIVED
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Limitations and Caveats
2 sets of duplicates(4 patients(pts)) were counted only once.652 sites were initiated and 611 enrolled.One site transferred all pts to other sites.27 pts randomised and 13 pts screened were excluded from analyses due to serious non-compliance
Results Point of Contact
- Title
- Boehringer Ingelheim Call Center
- Organization
- Boehringer Ingelheim
Study Officials
- STUDY CHAIR
Boehringer Ingelheim
Boehringer Ingelheim
Publication Agreements
- PI is Sponsor Employee
- No
- Restriction Type
- OTHER
- Restrictive Agreement
- Yes
Study Design
- Study Type
- interventional
- Phase
- phase 3
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
May 26, 2010
First Posted
May 27, 2010
Study Start
July 1, 2010
Primary Completion
April 1, 2015
Study Completion
April 1, 2015
Last Updated
May 16, 2016
Results First Posted
May 16, 2016
Record last verified: 2016-04